Application of baicalein in preparation of medicine for preventing and treating obesity and complications thereof

A technology of baicalein and obesity, which is applied in the field of application of baicalein in the preparation of drugs for preventing and treating obesity and its complications, and can solve the problems of preventing and/or treating obesity and its complications by baicalein

Pending Publication Date: 2020-12-01
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the prior art does not disclose the use of baicalein to prevent and / or treat obesity and its complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of baicalein in preparation of medicine for preventing and treating obesity and complications thereof
  • Application of baicalein in preparation of medicine for preventing and treating obesity and complications thereof
  • Application of baicalein in preparation of medicine for preventing and treating obesity and complications thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0049] Experimental example 1. Effects of two crystal forms of baicalein on body weight and food intake of obese mice induced by high-fat diet

[0050] Experimental method: Changes in body weight, food intake and water intake of mice were recorded every week.

[0051] Experimental results: After being fed with high-fat diet, the weight of the mice gradually increased. After 4 weeks of feeding, the weight of the mice in the high-fat diet-induced obesity group increased significantly, which was statistically different from that of the normal control group. The two crystalline forms of baicalein were administered continuously for 8 weeks, gradually reducing the weight growth rate of obese mice induced by high-fat diet, and the anti-obesity biological activity of the β crystalline form was greater than that of the α crystalline form at the same dose (250 mg / kg) ( figure 1 ,Table 1). After 5 weeks of continuous administration of the two crystal forms of baicalein, the body weight ...

experiment example 2

[0068] Experimental example 2. Effect of two crystal forms of baicalein on body fat rate of obese mice induced by high-fat diet

[0069] Experimental method: NMR method was used to detect the body fat percentage of mice. The higher the body fat percentage, the more serious the obesity of the mice. The body fat percentage decreased, indicating that the obesity status of the mice had improved.

[0070] Experimental results: Compared with the normal control group, the body fat rate of the model control group was significantly increased (P Figure 6 , Table 6).

[0071] Table 6 Effects of two crystal forms of baicalein on the body fat rate of obese mice induced by high-fat diet.

[0072]

[0073]Note: n=8-10, mean±SEM, t test was used for statistical analysis. ***P<0.001 (compared with normal control group), #P<0.05 (compared with model control group), ##P<0.01 (compared with model control group), ###P<0.001 (compared with model control group) compared to the model control gr...

experiment example 3

[0074] Experimental example 3. Effects of two crystal forms of baicalein on glucose metabolism in obese mice induced by high-fat diet

[0075] 3.1 Effects of two crystalline forms of baicalein administered for 4 weeks on fasting blood glucose in obese mice induced by high-fat diet

[0076] Experimental method: After 4 weeks of continuous administration of the two crystal forms of baicalein, the mice were fasted from 8:00 am, administered orally at 10:00, and blood was collected from the tip of the tail at 12:00. Determination of fasting blood glucose level in mice with Fulishan blood glucose test paper.

[0077] Experimental results: Compared with the normal control group, the fasting blood glucose of the mice in the model control group was significantly higher (P Figure 7 , Table 7).

[0078] Table 7 Effect of administration of two crystalline forms of baicalein for 4 weeks on fasting blood sugar in obese mice induced by high-fat diet.

[0079]

[0080] Note: n=8-10, mea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of baicalein in prevention and / or treatment of obesity and complications thereof in an alpha crystal form, a beta crystal form or an (alpha + beta) mixed crystal form. The invention particularly relates to the application of baicalein alpha crystal form, beta crystal form or (alpha + beta) mixed crystal form substances serving as active ingredients in treatmentof obesity and complications such as insulin resistance, blood glucose and / or dyslipidemia and the like thereof as well as a solid medicine form used for clinical application, which is prepared through combination of the baicalein alpha crystal form, beta crystal form or the (alpha + beta) mixed crystal form substances used as active ingredients and other active ingredients and excipients within aweight range of 0.001-2000 mg / kg every day.

Description

technical field [0001] The invention relates to the application of baicalein alpha crystal form, beta crystal form or (alpha+beta) mixed crystal form substance in the preparation of medicines for preventing and / or treating obesity and its complications. Mainly about baicalein α crystal form, β crystal form or (α+β) mixed crystal form substances in the preparation of drugs for the prevention and / or treatment of obesity and obesity complications such as insulin resistance, glucose metabolism and / or lipid metabolism abnormalities Applications. Background technique [0002] Obesity is a long-term chronic metabolic disease caused by an imbalance between energy intake and expenditure. In recent years, lifestyle changes, reduced physical activity and widespread intake of high-calorie foods have resulted in a positive energy balance in contemporary humans. Excess and unutilized food ingested is converted into lipid components and stored in the liver, fat and other tissues. The in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P3/04A61P3/00A61P3/10A61P3/06A61P5/50
CPCA61K31/352A61P3/04A61P3/00A61P3/10A61P3/06A61P5/50
Inventor 杜冠华强桂芬何萍侯碧玉徐春阳吕扬杨秀颖张莉周启蒙
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap